GSK PLC ORD GBP0.3125
Symbol: GSK
Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.
Invest in this share within an ISA, JISA, SIPP or Investment Account
Overview
Core Data
Latest Dividend Information
| Ex-Dividend Date | 16 May 2024 |
| Pay Date | 11 Jul 2024 |
| Total Dividends - Year to Date | 58 |
| Dividend Yield (%) | 3.513 |
Historical Data & Ratios
| Avg Volume Over 10 Days | 6.8858 |
| Market Cap (M) | 67955.3000 |
| Price/Earnings (PE) | 13.6751 |
| Earnings Per Share | 120.73 |
| Revenue Per Share | 7.3773 |
| Return on Equity % | 41.1610 |
1 Month Performance Chart
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy8 |
Buy5 |
Neutral9 |
Sell2 |
Strong Sell0 |
|---|---|---|---|---|---|
| Brokers | 8 | 5 | 9 | 2 | 0 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
Cost and Charges Information
This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product
Account Type
Annual charges
These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate
| Cost Category | % of Investment | lump sum costs |
|---|---|---|
Our annual fee
Our annual feeIncludes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here |
0.35% | |
Dealing charges
Dealing chargesAny one-off commission charges associated with investing. Note that government taxes and levies are not included |
N/A | |
Product provider costs
Product provider costsProduct provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs |
N/A | N/A |
Total (£)
Total (£)Costs per annum displayed in monetary value |
||
Total (%)
Total (%)Costs per annum displayed as a percentage of investment value |
||
Cumulative effect of charges on your investment's return
This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges
| lump sum invested with an assumed growth rate of | 1 year | years |
|---|---|---|
What you might get back at with no charges applied
What you might get back at with no charges appliedThese are the illustrative values of a investment after growth and no costs applied at the end of the defined period |
||
Annual charges
Annual chargesThese are the annual costs based on an initial investment amount of assuming a net zero growth rate |
||
Effect of charges on return (%)
Effect of charges on return (%)These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate |
||
Effect of charges on return (£)
Effect of charges on return (£)These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate |
||
What you might get back at with charges applied
What you might get back at with charges appliedThese are the illustrative values of a investment after growth and costs at the end of the defined period |
This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use
Charts
Company
Business Summary
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Financial Summary
BRIEF: For the fiscal year ended 31 December 2023, GSK plc revenues increased 3% to £30.33B. Net income before extraordinary items increased 16% to £4.93B. Revenues reflect US segment increase of 9% to £15.82B. Net income benefited from Commercial Operations segment income increase of 8% to £14.66B, Unallocated segment loss decrease of 31% to £263M. Dividend per share decreased from £0.61 to £0.58.
Financials
Income Statement - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Revenue | 30,328.00 | 29,324.00 | 24,696.00 | 24,354.00 | 33,754.00 | 30,821.00 |
| Gross profit | 21,965.00 | 20,857.00 | 16,690.00 | 17,033.00 | 23,586.00 | 21,249.00 |
| Operating Profit/Loss | 6,746.00 | 6,433.00 | 4,321.00 | 5,979.00 | 6,961.00 | 5,486.00 |
| Profit Before Tax | 6,064.00 | 5,628.00 | 3,599.00 | 5,170.00 | 6,221.00 | 4,800.00 |
| Profit After Tax | 5,308.00 | 4,921.00 | 3,516.00 | 5,103.00 | 5,268.00 | 3,921.00 |
| Equity Holders of Parent Company | 4,928.00 | 14,956.00 | 4,385.00 | 5,749.00 | 4,645.00 | 3,623.00 |
| Minority Interest | -932.00 | -1,167.00 | 5,576.00 | 5,582.00 | 6,329.00 | -1,111.00 |
Balance Sheet - All values are in GBP (M).
|
Year Ending |
31/12/2023 |
31/12/2022 |
31/12/2021 |
31/12/2020 |
31/12/2019 |
31/12/2018 |
|---|---|---|---|---|---|---|
| Total Non-Current Assets | 40,361.00 | 39,377.00 | 60,429.00 | 60,184.00 | 60,201.00 | 41,139.00 |
| Total Current Assets | 18,644.00 | 20,769.00 | 18,674.00 | 20,247.00 | 19,491.00 | 16,927.00 |
| Total Assets | 59,005.00 | 60,146.00 | 79,103.00 | 80,431.00 | 79,692.00 | 58,066.00 |
| Total Liabilities | 46,210.00 | 50,050.00 | 57,761.00 | 59,623.00 | 61,335.00 | 54,394.00 |
| Total Net Assets | 12,795.00 | 10,096.00 | 21,342.00 | 20,808.00 | 18,357.00 | 3,672.00 |
| Shareholders Funds | 13,347.00 | 10,598.00 | 15,055.00 | 14,587.00 | 11,405.00 | 4,360.00 |
| Minority Interests | -932.00 | -1,167.00 | 5,576.00 | 5,582.00 | 6,329.00 | -1,111.00 |
| Total Equity | 12,795.00 | 10,096.00 | 21,342.00 | 20,808.00 | 18,357.00 | 3,672.00 |
Outlook
Broker View
Data shown is based on the past 75 days of broker views.
|
ActionBrokers |
Strong Buy8 |
Buy5 |
Neutral9 |
Sell2 |
Strong Sell0 |
|---|---|---|---|---|---|
| Brokers | 8 | 5 | 9 | 2 | 0 |
| Consensus |
ConsensusBuy |
||||
Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.
© 2022 Refinitiv, an LSEG business. All rights reserved.
Forecasts
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | £31,875.80mn | £33,446.40mn | £35,112.30mn |
| Pre-tax-Profit | £8,675.36mn | £9,646.65mn | £10,666.00mn |
| EPS | £1.55p | £1.75p | £1.93p |
| EPS Growth | 0.07% | 12.90% | 9.98% |
| P/E | 10.2 | 9.12 | 8.34 |
| PEG Ratio | 139.75 | 0.71 | 0.84 |
| Dividend | 60.76p | 64.78p | 69.18p |
| Yield | 0.00% | 0.00% | 0.00% |
Upgrades & Downgrades (Latest)
| Date | Broker | Recommendation | Price | Old Target | New Target | Change |
|---|---|---|---|---|---|---|
| 17th Apr 2024 | Deutsche | Reiteration | 1590p | 0p | 1950p | Buy |
| 8th Apr 2024 | Barclays | Reiteration | 1620p | 0p | 1725p | Equal-weight |
| 12th Mar 2024 | Deutsche | Reiteration | 1685p | 0p | 1950p | Buy |
| 7th Mar 2024 | Shore Capital | Reiteration | 1711p | 0p | 0p | Buy |
| 27th Feb 2024 | Deutsche | Reiteration | 1671p | 0p | 1950p | Buy |
| 15th Feb 2024 | Shore Capital | Reiteration | 1663p | 0p | 0p | Buy |
| 14th Feb 2024 | Berenberg Bank | Reiteration | 1668p | 1650p | 1820p | Buy |
| 9th Feb 2024 | Barclays | Reiteration | 1660p | 0p | 1950p | Buy |
| 31st Jan 2024 | Shore Capital | Reiteration | 1568p | 0p | 0p | Buy |
| 18th Dec 2023 | Barclays | Reiteration | 1443p | 0p | 1575p | Equal-weight |
Time & Sales
All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.
| Date | Time | Price | Volume | Type |
|---|---|---|---|---|
| 24 Apr 2024 | 09:20 | 1,655 | 513 | Sell |
| 24 Apr 2024 | 09:20 | 1,655 | 100 | Sell |
| 24 Apr 2024 | 09:20 | 1,655 | 196 | Sell |
| 24 Apr 2024 | 09:20 | 1,655 | 459 | Sell |
| 24 Apr 2024 | 09:20 | 1,654.5 | 67 | Sell |
| 24 Apr 2024 | 09:20 | 1,654.5 | 239 | Sell |
| 24 Apr 2024 | 09:20 | 1,654.5 | 106 | Sell |
| 24 Apr 2024 | 09:20 | 1,655 | 230 | Buy |
| 24 Apr 2024 | 09:20 | 1,655 | 407 | Buy |
| 24 Apr 2024 | 09:20 | 1,655 | 235 | Buy |
| 24 Apr 2024 | 09:20 | 1,655 | 297 | Buy |
| 24 Apr 2024 | 09:20 | 1,655 | 82 | Buy |
| 24 Apr 2024 | 09:20 | 1,655 | 6 | Sell |
| 24 Apr 2024 | 09:20 | 1,655.589 | 604 | Buy |
| 24 Apr 2024 | 09:19 | 1,655.5 | 100 | Sell |
| 24 Apr 2024 | 09:19 | 1,655.5 | 232 | Sell |
| 24 Apr 2024 | 09:19 | 1,655.5 | 31 | Sell |
| 24 Apr 2024 | 09:19 | 1,655.5 | 27 | Sell |
| 24 Apr 2024 | 09:19 | 1,655.5 | 258 | Sell |
| 24 Apr 2024 | 09:19 | 1,655.5 | 273 | Sell |
Selected data supplied by Thomson Reuters © View restrictions.